Financial Performance - The company's gross loss decreased from approximately RMB 39.2 million for the year ended December 31, 2021, to a gross loss of approximately RMB 24.7 million for the year ended December 31, 2022, primarily due to inventory impairment related to chronic hepatitis C products[3]. - The company reported a net loss of RMB 314.8 million for the year ended December 31, 2022, compared to a net loss of RMB 199 million for the year ended December 31, 2021, with the increase attributed to inventory and intangible asset impairments related to chronic hepatitis C products[51]. - The company's total revenue decreased by 29.6% from approximately RMB 769 million for the year ended December 31, 2021, to approximately RMB 541 million for the year ended December 31, 2022, primarily due to the termination of promotional services for Palvico® to Roche Pharmaceuticals in China[42]. - The company reported a net loss margin of (582.1)% for the year ended December 31, 2022, compared to (258.9)% for the previous year, highlighting deteriorating profitability[40]. - The gross profit for 2022 was approximately RMB 23.9 million, with a gross margin of 44.1%, down from 61.0% in 2021[102]. - The total comprehensive loss for the year was RMB 193.3 million, compared to RMB 231.0 million in the previous year[193]. Research and Development - Research and development expenses increased by 25.2% from approximately RMB 213.3 million for the year ended December 31, 2021, to approximately RMB 267.1 million for the year ended December 31, 2022, driven by continued investment in antiviral candidates for COVID-19 and chronic hepatitis B functional cure[9]. - The total research and development costs for viral diseases amounted to approximately RMB 144.8 million for the year ended December 31, 2022, compared to RMB 67.3 million for the year ended December 31, 2021[12]. - The company achieved 13 IND approvals from the National Medical Products Administration of China and the FDA, advancing 2 new candidate drugs into Phase II and supporting 6 candidates in ongoing Phase II or III clinical development[43]. - The company is expanding its clinical pipeline with a focus on innovative therapies for chronic hepatitis and viral infections[1]. - The ASC22 clinical trial for chronic hepatitis B patients is based on a randomized, single-blind, multi-center design with 75 patients[81]. - The ASC40 (denifanstat) Phase IIb clinical trial for NASH patients showed statistically significant improvement in multiple key disease markers after 26 weeks of treatment[85]. Financial Position - The company's total assets decreased from approximately RMB 21.0 million as of December 31, 2021, to approximately RMB 18.3 million as of December 31, 2022[22]. - Cash and cash equivalents increased significantly from approximately RMB 768.1 million in 2021 to approximately RMB 2,067.1 million in 2022, reflecting improved liquidity[26]. - The company has approximately RMB 2,470.8 million in cash and cash equivalents as of December 31, 2022, sufficient to support R&D activities and operations until 2027[70]. - The company had no debt as of December 31, 2022, indicating a strong balance sheet position[154]. - The total current assets decreased from RMB 2,631.6 million in 2021 to RMB 2,544.7 million in 2022[194]. - The company's total liabilities included other payables amounting to RMB 101.05 million, an increase from RMB 86.76 million as of December 31, 2021[144]. Operational Efficiency - The company's administrative expenses rose by 17.5% from approximately RMB 29.9 million for the year ended December 31, 2021, to approximately RMB 35.2 million for the year ended December 31, 2022[6]. - Sales and distribution expenses decreased by 18.6% from approximately RMB 20.9 million for the year ended December 31, 2021, to approximately RMB 17.0 million for the year ended December 31, 2022[5]. - Other expenses significantly increased by 172.7% from approximately RMB 21.9 million for the year ended December 31, 2021, to approximately RMB 59.8 million for the year ended December 31, 2022, mainly due to increased impairment of other intangible assets[13]. - The company's financing costs were approximately RMB 0.2 million for the year ended December 31, 2022, up from RMB 0.1 million in the previous year, reflecting increased lease liabilities[32]. Market and Product Development - The company has signed commercialization supply agreements for Ritonavir with domestic and multinational pharmaceutical companies, which are expected to significantly contribute to total revenue in 2023[60]. - The ASC10 has received FDA approval to conduct a Phase IIa clinical trial for RSV infection, with completion expected in Q4 2023 in either the US or China[63][64]. - The company has expanded its production capacity for ritonavir oral tablets to approximately 530 million tablets per year[80]. - The company has obtained exclusive rights for ASC40 and ASC60 in the Greater China region from Sagimet Biosciences[57]. - The company plans to accelerate the clinical trials for multiple products, including ASC22 for chronic hepatitis B and ASC40 for acne, with Phase II or III trials expected to commence[125]. Employee and Organizational Structure - The total number of employees as of December 31, 2022, was 278, with 60% in R&D and 19% in operations[161]. - The company had 278 employees as of December 31, 2022, with over 76% holding a bachelor's degree or higher[187]. - Total employee cost for 2022 was approximately RMB 127.0 million, up from RMB 110.6 million in 2021[187]. Risks and Challenges - The company faced foreign exchange risks primarily from USD, with no currency hedging transactions in place during the reporting period[160]. - The company reported a foreign exchange risk due to fluctuations in the exchange rates affecting its financial condition and operating performance[185].

歌 ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 ( 於開曼群島註冊成立的有限公司) 股份代號：1672 2022 中期報告 | --- | --- | |-------|--------------------------| | | | | 目 | 錄 | | | | | 2 | 公司資料 | | 4 | 財務概要 | | 5 | 管理層討論及分析 | | 36 | 其他資料 | | 41 | 獨立審閱報告 | | 42 | 中期簡明綜合損益表 | | 43 | 中期簡明綜合收益表 | | 44 | 中期簡明綜合財務狀況表 | | 45 | 中期簡明綜合權益變動表 | | 46 | 中期簡明綜合現金流量表 | | 48 | 中期簡明綜合財務資料附註 | | 60 | 釋義 | 歌禮製藥有限公司 2 公司資料 | --- | --- | |--------------------------------------------------|--------------------------------------------| | | | | 董事會 | 註冊辦 ...

歌 ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 | --- | --- | |-----------------------------------------------|---------------| | | | | | | | (於開曼群島註冊成立的有限公司) 股份代號：1672 | 年度報告 2021 | 目 錄 | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------|-------|-------| | | | | | | | | | | 2 | 公司資料 | | | | | | 4 | 主席報告書 | | | | | | 6 | 財務概要 | | | | | | 7 | 公司簡介 | | | | | | 10 | 管理層討論與分析 | | | | | | 35 | 董事及高級管理層 | | | | | | 39 | 董事會報告 | | | | | | 56 | 企業管治報告 | | | | | | 69 | 環境、社會及管治報告 | ...

歌 ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 (於開曼群島註冊成立的有限公司) 股份代號：1672 期 報 告 2021 中 目 錄 2 公司資料 4 財務概要 5 公司簡介 9 管理層討論及分析 30 其他資料 35 獨立審閱報告 36 中期簡明綜合損益表 37 中期簡明綜合收益表 38 中期簡明綜合財務狀況表 39 中期簡明綜合權益變動表 40 中期簡明綜合現金流量表 42 中期簡明綜合財務資料附註 53 釋義 歌禮製藥有限公司 2 公司資料 | --- | --- | |-----------------------|-----------------------------| | | | | 董事會 | 註冊辦事處 | | | | | 執行董事 | Walkers Corporate Limited | | | 190 Elgin Avenue | | 吳勁梓博士 | George Town | | （主席兼行政總裁） | Grand Cayman KY1-9008 | | 何淨島女士 （副總裁） | Cayman Islands 中國公司總部 | | ...

部次 ill ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 · 。(於開曼群島註冊成立的有限公司) ● 股份代號：1672 · o o oto 年 度 報 告 2020 | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|----------------------| | | | | | | | | | | | | 目 | 錄 | | | | | | | | | | | | | 2 | 公司資料 | | | | | | 4 | 主席報告書 | | | | | | 5 | 財務概要 | | | | | | 6 | 公司簡介 | | | | | | 9 | 管理層討論與分析 | | | | | | | | | | | | | 29 | 董事及高級管理層 | | | | | | | | | | | | | 33 | 董事會報告 | | | | | | | | | | | | | 50 | 企業管治報告 | | | | | | 63 | 環境、社會及管治報告 | | ...

歌 ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 (於開曼群島註冊成立的有限公司) 股份代號：1672 c 目 錄 2 公司資料 4 財務概要 5 公司簡介 8 管理層討論及分析 30 其他資料 36 獨立審閱報告 37 中期簡明綜合損益表 38 中期簡明綜合收益表 39 中期簡明綜合財務狀況表 40 中期簡明綜合權益變動表 41 中期簡明綜合現金流量表 43 中期簡明綜合財務資料附註 51 釋義 歌禮製藥有限公司2 公司資料 | --- | --- | |--------------------|--------------------------------| | | | | 董事會 | 註冊辦事處 | | 執行董事 | 轉交 Walkers Corporate Limited | | | | | | Cayman Corporate Centre | | 吳勁梓博士 | 27 Hospital Road | | （主席兼行政總裁） | George Town | | 何淨島女士 | Grand Cayman KY1-9008 | | （副總裁） | Caym ...

歌 ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 (於開曼群島註冊成立的有限公司) 股份代號：1672 年度 報 告 2019 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | 目 | 錄 | | | | | | | | | | 2 4 | 公司資料 主席報告書 | | | | | | | | | | 5 | 財務概要 | | | | | | | | | | | | | | | | | | | | | 6 | 公司簡介 | | | | | | | | | | 8 | 管理層討論與分析 | | | | | | | | | | 26 | 董事及高級管理層 | | | | | | | | | | 31 | 董事會報告 ...

歌 ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 (於開曼群島註冊成立的有限公司) 股份代號：1672 中 期 報 告 2019 目 錄 2 公司資料 4 財務概要 5 公司簡介 7 管理層討論及分析 30 其他資料 36 獨立審閱報告 37 中期簡明綜合損益表 38 中期簡明綜合收益表 39 中期簡明綜合財務狀況表 40 中期簡明綜合權益變動表 41 中期簡明綜合現金流量表 43 中期簡明綜合財務報表附註 55 釋義 公司資料 | --- | --- | |-------------------------------|---------------------------------------------------| | | | | 董事會 | 註冊辦事處 | | 執行董事 | 轉交 Walkers Corporate Limited | | | Cayman Corporate Centre | | 吳勁梓博士 （主席兼行政總裁） | 27 Hospital Road | | | George Town | | 何凈島女士 （副總裁） | Grand C ...

年 度 報 告 ２０１８ 歌 il ascletis Ascletis Pharma Inc. 歌 禮 製 藥 有 限 公 司 (於開曼群島註冊成立的有限公司) 股份代號：1672 目 錄 2 公司資料 4 主席報告書 5 財務概要 6 公司簡介 8 管理層討論與分析 27 董事及高級管理層 32 董事會報告 45 企業管治報告 57 獨立核數師報告 62 綜合損益表 63 綜合全面收益表 64 綜合財務狀況表 65 綜合權益變動表 66 綜合現金流量表 68 財務報表附註 131 釋義 | --- | --- | --- | |-----------------------------------------|------------------------------------------------------|---------------------------------------------------| | | | | | | | 歌禮製藥有限公司 | | | | | | | | 公司資料 | | 董事會 | 註冊辦事處 | | | | 轉交 | Walkers Corporate Lim ...